PMID- 36238577 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20221015 IS - 1663-9812 (Print) IS - 1663-9812 (Electronic) IS - 1663-9812 (Linking) VI - 13 DP - 2022 TI - Efficacy and safety of Chinese herbal medicine for atopic dermatitis: Evidence from eight high-quality randomized placebo-controlled trials. PG - 927304 LID - 10.3389/fphar.2022.927304 [doi] LID - 927304 AB - Background: The use of Chinese herbal medicine (CHM) for the treatment of atopic dermatitis (AD) has gained attention. This quantitative study systematically evaluated the efficacy and safety of CHM for the treatment of AD in eight high-level clinical trials, resulting in a high level of clinical evidence. Methods: Several databases were searched, including PubMed, Embase, Cochrane Library, Web of Science, China National Knowledge Infrastructure (CNKI), the Chongqing VIP Chinese Science (VIP), and Wanfang Database. High-quality randomized controlled trials (RCTs) comparing CHM with placebo were included. The 95% confidence interval (CI) of the risk ratio (RR) was calculated using software (RevMan 5.3) and a meta-analysis was performed. Evidence level evaluation using GRADE Profiler 3.6. Results: In total, 662 patients (322 in the experimental group and 340 in the control group) were included. The response rate of the Eczema Area and Severity Index (EASI) -90 was higher in the CHM group than in the placebo group (RR, 3.72; 95% CI, 1.76 to7.83; p = 0.01). Furthermore, the scoring of atopic dermatitis (SCORAD) (RR, -10.20), body surface area (BSA) (RR, -2.01), surface damage score (RR, -2.25), visual analog scale (VAS) (RR, -1.90), and sleep score (RR, -2.16), improvement of investigator's global assessment (IGA) (RR, 2.94) improved in the CHM group. The results showed no statistical difference between CHM and placebo (MD, -0.47; 95% CI, -1.30, 0.37; p = 0.27) in improving the Dermatology Life Quality Index (DLQI) or children's DLQI (CDLQI). There was also no significant difference in the IgE level between the two groups (MD, -62.76; 95% CI, -809.58, 684.05; p = 0.87). However, the adverse events (AEs) rate was slightly higher in patients treated with CHM than in those treated with placebo (RR, 1.42; 95% CI, 1.06-1.90; p = 0.02). Conclusion: CHM improved the size and severity of the skin lesions and sleep quality in patients with AD. Comparing the adverse effects between the two groups, CHM is safe. However, CHM does not improve the quality of life or the patient's IgE levels. CI - Copyright (c) 2022 Cai, Sun, Liu, Zhou, Hong, Wang, Chen, Zhang, Wang, Lin, Li, Xu and Li. FAU - Cai, Xiaoce AU - Cai X AD - Department of Dermatology, Yueyang Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai, China. AD - Institute of Dermatology, Shanghai Academy of Traditional Chinese Medicine, Shanghai, China. FAU - Sun, Xiaoying AU - Sun X AD - Department of Dermatology, Yueyang Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai, China. AD - Institute of Dermatology, Shanghai Academy of Traditional Chinese Medicine, Shanghai, China. FAU - Liu, Liu AU - Liu L AD - Department of Dermatology, Yueyang Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai, China. AD - Institute of Dermatology, Shanghai Academy of Traditional Chinese Medicine, Shanghai, China. FAU - Zhou, Yaqiong AU - Zhou Y AD - Department of Dermatology, Yueyang Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai, China. AD - Institute of Dermatology, Shanghai Academy of Traditional Chinese Medicine, Shanghai, China. FAU - Hong, Seokgyeong AU - Hong S AD - Department of Dermatology, Yueyang Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai, China. AD - Institute of Dermatology, Shanghai Academy of Traditional Chinese Medicine, Shanghai, China. FAU - Wang, Jiao AU - Wang J AD - Department of Dermatology, Yueyang Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai, China. AD - Institute of Dermatology, Shanghai Academy of Traditional Chinese Medicine, Shanghai, China. FAU - Chen, Jiale AU - Chen J AD - Department of Dermatology, Yueyang Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai, China. FAU - Zhang, Miao AU - Zhang M AD - Department of Dermatology, Yueyang Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai, China. AD - Institute of Dermatology, Shanghai Academy of Traditional Chinese Medicine, Shanghai, China. FAU - Wang, Chunxiao AU - Wang C AD - Department of Dermatology, Yueyang Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai, China. AD - Institute of Dermatology, Shanghai Academy of Traditional Chinese Medicine, Shanghai, China. FAU - Lin, Naixuan AU - Lin N AD - Department of Dermatology, Yueyang Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai, China. FAU - Li, Su AU - Li S AD - Department of Dermatology, Yueyang Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai, China. FAU - Xu, Rong AU - Xu R AD - Department of Dermatology, Yueyang Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai, China. FAU - Li, Xin AU - Li X AD - Department of Dermatology, Yueyang Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai, China. AD - Institute of Dermatology, Shanghai Academy of Traditional Chinese Medicine, Shanghai, China. LA - eng PT - Systematic Review DEP - 20220927 PL - Switzerland TA - Front Pharmacol JT - Frontiers in pharmacology JID - 101548923 PMC - PMC9551201 OTO - NOTNLM OT - Chinese herbal medicine OT - atopic dermatitis OT - efficacy OT - randomized controlled trials OT - safety COIS- The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. EDAT- 2022/10/15 06:00 MHDA- 2022/10/15 06:01 PMCR- 2022/09/27 CRDT- 2022/10/14 03:08 PHST- 2022/04/24 00:00 [received] PHST- 2022/08/29 00:00 [accepted] PHST- 2022/10/14 03:08 [entrez] PHST- 2022/10/15 06:00 [pubmed] PHST- 2022/10/15 06:01 [medline] PHST- 2022/09/27 00:00 [pmc-release] AID - 927304 [pii] AID - 10.3389/fphar.2022.927304 [doi] PST - epublish SO - Front Pharmacol. 2022 Sep 27;13:927304. doi: 10.3389/fphar.2022.927304. eCollection 2022.